Agitation thrombolysis and catheter-directed thrombolysis for normotensive patients with acute pulmonary thromboembolism.
To assess the feasibility, efficacy, and safety of agitation thrombolysis and catheter-directed thrombolysis (AT-CDT) in the treatment of normotensive patients with acute pulmonary thromboembolism (PTE). A total of 37 consecutive patients of normotensive PTE were treated by AT-CDT between October 2011 and January 2016. Clinical outcomes and mortality were evaluated after the treatment, and follow-up was carried out after hospital discharge. AT-CDT was technically successful in 93.7% (36/37) patients, with one case died from respiratory failure during procedure. The clinical success rate was 91.9% (34/37), one patient died from intracranial hemorrhage 9 days after agitation, and one case showed no improvement. A total of 83.8% (31/37) cases were clinical cured and 8.1% (3/37) cases were relieved during hospitalization. Three cases died of respiratory failure caused by PTE, and two cases died of diseases unrelated to PTE (lung carcinoma/hemoptysis) during a 20-1524 days of follow-up. AT-CDT may be a feasible, effective, and safe treatment for normotensive patients with acute PTE.